

[Ethionamide](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J04AD03](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Ethionamide

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid > dispersible tablet: 125 mg (EMLc)

Oral > Solid > tablet: 250 mg

EML status history

First added in 1982 ([TRS 685](#))

Removed in 1987 ([TRS 770](#))

Added in 1999 ([TRS 895](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2013 ([TRS 985](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[protionamide](#) (ATC codes: [J04AD01](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Ethionamide](#)

DrugBank

[Ethionamide](#)

Summary of evidence and Expert Committee recommendations



The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.